Kaohsiung, Taiwan

Chiu-Lien Hung

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Industrial Technology Research Institute. Active years: 2023-2024.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.5

ph-index = 1


Company Filing History:


Years Active: 2023-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Chiu-Lien Hung: Innovator in Pharmaceutical Chemistry

Introduction

Chiu-Lien Hung is a notable inventor based in Kaohsiung, Taiwan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds with therapeutic applications. With a total of 2 patents to her name, her work continues to impact the industry.

Latest Patents

Chiu-Lien Hung's latest patents include an androgen receptor binding molecule and a beta-amino acid derivative that serves as a kinase inhibitor. The androgen receptor binding molecule features a complex structure that allows for specific interactions with androgen receptors, which are crucial in various biological processes. The beta-amino acid derivative is designed to inhibit kinase activity, providing a pharmaceutical composition that can be utilized in various in vivo applications.

Career Highlights

Chiu-Lien Hung is affiliated with the Industrial Technology Research Institute, where she conducts her research and development activities. Her work is characterized by a strong focus on creating innovative solutions that address pressing health challenges.

Collaborations

Chiu-Lien collaborates with esteemed colleagues such as Chih-Wei Fu and Chien-Chin Huang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Chiu-Lien Hung's contributions to pharmaceutical chemistry exemplify the spirit of innovation in the field. Her patents reflect her commitment to advancing medical science and improving therapeutic options for patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…